- Home
- AMRN vs PROK Comparison
AMRN vs PROK Comparison
Compare AMRN & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMRN | PROK |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 304.3M | 359.1M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMRN | PROK |
|---|---|---|
| Price | $14.36 | $1.85 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $12.00 | $7.40 |
| AVG Volume (30 Days) | 39.6K | ★ 852.5K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $181,104,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 39.22 | ★ 1075.00 |
| 52 Week Low | $11.67 | $0.54 |
| 52 Week High | $20.90 | $7.13 |
Technical Indicators
Market Signals| Indicator | AMRN | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 53.00 |
| Support Level | $14.34 | $1.73 |
| Resistance Level | $15.39 | $2.58 |
| Average True Range (ATR) | 0.48 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 51.68 | 84.21 |
Price Performance
Historical ComparisonAbout AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.